Literature DB >> 11967808

Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors.

P M Vanderheyden1, I Verheijen, F L Fierens, J P Backer, G Vauquelin.   

Abstract

The aim of the present work was to investigate the binding properties of the selective AT(1)-receptor antagonist irbesartan to human AT(1)-receptors by direct radioligand binding. For this purpose the specific binding of [(3)H]-irbesartan to intact Chinese Hamster Ovary (CHO) cells expressing human recombinant AT(1)-receptors was determined. Specific binding of [(3)H]-irbesartan rapidly reached equilibrium and was saturable with a KD of 1.94 +/- 0.12 to a homogeneous class of binding sites. Its binding was inhibited by other AT(1) antagonists (AIIAs) with the same potency order as previous results from [(3)H]-angiotensin II and [(3)H]-candesartan binding to human AT(1)-receptors. Whereas the dissociation rate of [(3)H]-irbesartan was essentially independent of the radioligand concentration, it was much slower at 12 degrees C when compared with 37 degrees C. Moreover, the dissociation rate was similar, as determined in washout experiments in the absence or presence of unlabelled AT(1) antagonists. At 37 degrees C the dissociation rate constant corresponded to a half-life of approximately seven minutes, which is sufficient to explain the partially insurmountable inhibition by irbesartan in previous studies. In contrast, other phenomena such as the plasma half life and tissue-related factors are necessary to explain its sustained in vivo antihypertensive effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11967808     DOI: 10.3317/jraas.2000.020

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  4 in total

Review 1.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 2.  Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

Authors:  Tianjing Ren; Xu Zhu; Natalie M Jusko; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-30       Impact factor: 2.410

3.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Authors:  M T Le; M K Pugsley; G Vauquelin; I Van Liefde
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

4.  Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.

Authors:  Sandeep Singh; Annette K Offringa-Hup; Susan J J Logtenberg; Paul D Van der Linden; Wilbert M T Janssen; Hubertina Klein; Femke Waanders; Suat Simsek; Cornelis P C de Jager; Paul Smits; Machteld van der Feltz; Gerrit Jan Beumer; Christine Widrich; Martijn Nap; Sara-Joan Pinto-Sietsma
Journal:  Hypertension       Date:  2021-06-09       Impact factor: 10.190

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.